ACC: Antibody-Coated Stent Studied in Coronary Stenosis
Genous Endothelial Progenitor Cell-capturing stent shows high initial success rate
MONDAY, March 26 (HealthDay News) -- The Genous Endothelial Progenitor Cell-capturing stent, which is coated with an antibody that attracts circulating progenitor cells to help create a functioning endothelial layer, is a promising way to treat coronary stenosis, according to research presented this week at the American College of Cardiology meeting in New Orleans.
Marcel Beijk, M.D., of the University of Amsterdam in the Netherlands, and colleagues studied 87 patients who were treated with the stent after receiving statins for at least two weeks.
The researchers found that thrombolysis in myocardial infarction (TIMI) 3 flow was achieved in 99.3 percent of all treated lesions. They observed one side branch failure, which led to an in-hospital myocardial infarction. After six months, there was one additional myocardial infarction and the target vessel revascularization rate was 3.7 percent. Only three patients required a repeat percutaneous coronary intervention and two patients had a non-target vessel revascularization.
"While this is still an early study, it offers a whole new look at the use of stents and the process of healing damaged tissue throughout the body," Bejik said in a statement. "As we look at new treatment combinations, we believe this is a step in the right direction to offer patients better long-term success rates."